COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03680521
Recruitment Status : Active, not recruiting
First Posted : September 21, 2018
Last Update Posted : June 16, 2020
Information provided by (Responsible Party):
Mirati Therapeutics Inc.

Brief Summary:
The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the pre-surgical setting.

Condition or disease Intervention/treatment Phase
Clear Cell Renal Cell Carcinoma Drug: Sitravatinib Drug: Nivolumab Phase 2

Detailed Description:
Sitravatinib is a receptor tyrosine kinase inhibitor (TKI) that targets multiple closely related receptor tyrosine kinase pathways including VEGFR, PDGF receptor (PDGFR), c-KIT, MET, and the TAM family of receptors (TYRO3, AXL, and MER). Nivolumab is a monoclonal antibody directed against PD-1 and blocks the interaction between PD-1 and its ligands, thereby releasing PD-1-mediated inhibition of T-cell proliferation (including cytotoxic CD8+ T-cells) and cytokine production. Together, sitravatinib and nivolumab may cooperate to elicit greater anti-tumor activity than either agent alone, as sitravatinib is predicted to enhance several steps in the cancer immunity cycle that may augment the efficacy of nivolumab.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma
Actual Study Start Date : September 24, 2018
Actual Primary Completion Date : April 27, 2020
Estimated Study Completion Date : April 27, 2025

Arm Intervention/treatment
Experimental: Sitravatinib and nivolumab
Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks.
Drug: Sitravatinib
Sitravatinib oral capsule administered daily for 6-8 weeks.

Drug: Nivolumab
Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks.

Primary Outcome Measures :
  1. Percentage of patients achieving a point in time objective response (either complete or partial response [CR or PR]) prior to surgery. [ Time Frame: 6-8 weeks ]

Secondary Outcome Measures :
  1. Number of patients experiencing adverse events (number and percent of patients reporting AEs) [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Imaging results consistent with locally-advanced RCC
  2. Candidate for partial or complete nephrectomy as part of treatment plan.
  3. Measurable disease as per RECIST version 1.1.
  4. ECOG performance status 0 or 1.
  5. Adequate bone marrow and organ function.

Exclusion Criteria:

  1. Prior systemic anti-tumor treatment for RCC.
  2. Patients who are receiving any other investigational agents.
  3. Clinical status indicating that immediate surgery (within 6 weeks) is warranted regardless of whether neoadjuvant therapy is to be administered, as assessed by the treating surgeon.
  4. Inability to undergo baseline tumor biopsy.
  5. Active or prior documented autoimmune or immunocompromising conditions.
  6. Uncontrolled hypertension.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03680521

Layout table for location information
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Mirati Therapeutics Inc.
Layout table for additonal information
Responsible Party: Mirati Therapeutics Inc. Identifier: NCT03680521    
Other Study ID Numbers: 516-002
First Posted: September 21, 2018    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mirati Therapeutics Inc.:
Antineoplastic Agents
Immunologic factors
Tyrosine Kinase Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents